COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

NCT07449936

Status	RECRUITING
Phase	Phase 3
Sponsor	EyePoint Pharmaceuticals, Inc.
Enrollment	240 participants

Key Eligibility Criteria

Inclusion (3)

- Previously treated or treatment naïve patients with a documented diagnosis of macular edema associated with diabetic retinopathy (DR) in the study eye, with onset of disease that began at any time prior to the Screening Visit.
- Best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 35 letters (20/200 Snellen equivalent) to 78 letters (20/32 Snellen equivalent) in the study eye at the Screening Visit and at Baseline (Day 1).
- For previously treated participants: at least 1 injection of anti-VEGF in the past 12 months, the most recent anti-VEGF treatment for DME must not have been administered less than 12 weeks prior to the Screening Visit.

Exclusion (1)

- BCVA using ETDRS charts \<30 letters (20/250 Snellen equivalent) in the fellow eye.

Locations (3 total)

Global Research Management, Inc., Glendale, California, United States
Midwest Eye Institute - Carmel, Carmel, Indiana, United States
Mt. Olympus Medical Research, Houston, Texas, United States